Personalized one-two punches for lung cancer

Hannah A Scarborough; Paul A Bunn Jr; James DeGregori

doi:10.1038/cr.2014.168

Personalized one-two punches for lung cancer

Cell Res. 2015 Mar;25(3):269-70. doi: 10.1038/cr.2014.168. Epub 2014 Dec 30.

Authors

Hannah A Scarborough¹, Paul A Bunn Jr², James DeGregori³

Affiliations

¹ 1] Program in Molecular Biology, University of Colorado Cancer Center, Aurora, CO 80045, USA [2] Department of Biochemistry and Molecular Genetics, University of Colorado Cancer Center, Aurora, CO 80045, USA.
² Department of Medicine, School of Medicine, University of Colorado Cancer Center, Aurora, CO 80045, USA.
³ 1] Program in Molecular Biology, University of Colorado Cancer Center, Aurora, CO 80045, USA [2] Department of Biochemistry and Molecular Genetics, University of Colorado Cancer Center, Aurora, CO 80045, USA [3] Department of Medicine, School of Medicine, University of Colorado Cancer Center, Aurora, CO 80045, USA.

Abstract

Discovery of individualized therapies to address resistance to tyrosine kinase inhibitors (TKIs) has been hampered by the inability to test drug combinations on patient samples before and after TKI resistance. A recent study published in Science by Crystal et al. describes a methodology for pharmacological screening using a panel of 76 targeted agents and cell lines made directly from patient biopsies.

Publication types

Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Drug Resistance, Neoplasm / genetics*
Humans
Lung Neoplasms / drug therapy*
Molecular Targeted Therapy / methods*
Patient-Specific Modeling*
Protein Kinase Inhibitors / therapeutic use*

Substances

Protein Kinase Inhibitors

Abstract

Publication types

MeSH terms

Substances

Grants and funding